Infoods® IBS Study Results Published in Gastroenterology
Biomerica’s inFoods IBS test, a personalized dietary therapy for Irritable Bowel Syndrome (IBS), demonstrated statistically significant improvement in patient...
Dyne Therapeutics Presents New FSHD Preclinical Data
Dyne Therapeutics announced preclinical data showing its drug candidate, DYNE-302, improved muscle function in a mouse model of facioscapulohumeral...
Rectify Pharma Improves Kidney Function, Reduces Vascular Calcification
Rectify Pharmaceuticals presented data on RTY-822, a positive functional modulator (PFM) targeting the ABCC6 membrane transporter, at the 2025...
Actuate Doubles Survival in Pancreatic Cancer Trial
Actuate Therapeutics’ Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) achieved its primary endpoint, demonstrating a statistically significant...
Impact Biotech’s Padeliporfin Shows Promising Interim Results in Phase 3 Study
ImPact Biotech announced interim Phase 3 trial results for Padeliporfin VTP, a treatment for low-grade upper tract urothelial cancer...
Untreated Tardive Dyskinesia Rates High in Long-Term Care
A Teva-sponsored study reveals significant care gaps for tardive dyskinesia (TD) among long-term care (LTC) residents. More than half...
Sachi Phase III Hutchmed Highlights Data at ASCO 2025
HUTCHMED announced positive interim results from its SACHI Phase III study, showing that the combination of savolitinib and osimertinib...
Allogene Therapeutics Shows Durable Responses with Allo-316 in Advanced Renal Cell Carcinoma
Allogene Therapeutics presented positive Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy, for...
Replimune’s RP1 + Nivolumab Shows Promising Results in Melanoma Study
Replimune presented data from its IGNYTE trial at the 2025 ASCO meeting, showing promising results for RP1, an oncolytic...
Xilio Announces Updated Phase 2 Data for Vilastobart
Xilio Therapeutics announced updated Phase 2 clinical trial data for vilastobart, a tumor-activated anti-CTLA-4 therapy, combined with atezolizumab, in...